Literature DB >> 15450054

Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. The Bergen District Nursing Home Study.

Sabine Ruths1, Jørund Straand, Harald A Nygaard, Bjørn Bjorvatn, Ståle Pallesen.   

Abstract

OBJECTIVES: To explore the effect on sleep/wake activity and on behavioral and psychological symptoms of the withdrawal of antipsychotic medications from nursing home (NH) patients with dementia.
DESIGN: Randomized, placebo-controlled, double-blind trial.
SETTING: NHs in Bergen, Norway. PARTICIPANTS: Thirty patients (mean age 83.5) taking haloperidol, risperidone, or olanzapine for nonpsychotic symptoms. INTERVENTION: Study participants were randomly assigned to withdrawal (intervention group) or continued treatment with antipsychotic medications (reference group) for 4 consecutive weeks. MEASUREMENTS: Behavioral rating using the Neuropsychiatric Inventory Questionnaire (NPI-Q) and actigraphy.
RESULTS: After antipsychotic withdrawal, behavioral scores remained stable or improved in 11 of 15 patients, whereas four had worsening scores. Actigraphy revealed decreased sleep efficiency after drug discontinuation and increased 24-hour and night activity in both groups. Actigraphy records of nighttime and daytime activity indicated sleep problems and restlessness, in terms of the NPI-Q. One patient was restarted on antipsychotics.
CONCLUSION: Antipsychotic drug withdrawal affected activity and sleep efficiency over the short term. Increases in total activity and impaired sleep quality after drug discontinuation should be monitored, because the long-term effect of these changes is not known. The NPI-Q and actigraphy are feasible tools that disclose relevant changes occurring during antipsychotic withdrawal in NH patients with dementia. Their use in clinical practice should be substantiated by larger studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15450054     DOI: 10.1111/j.1532-5415.2004.52470.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  19 in total

Review 1.  Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned?

Authors:  Nathan Herrmann; Krista L Lanctôt
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 2.  Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying?

Authors:  Carole Parsons; Carmel M Hughes; A Peter Passmore; Kate L Lapane
Journal:  Drugs Aging       Date:  2010-06-01       Impact factor: 3.923

Review 3.  Pharmacotherapies for sleep disturbances in dementia.

Authors:  Jenny McCleery; Daniel A Cohen; Ann L Sharpley
Journal:  Cochrane Database Syst Rev       Date:  2016-11-16

Review 4.  Sleep Disturbance, Cognitive Decline, and Dementia: A Review.

Authors:  Alexandra M V Wennberg; Mark N Wu; Paul B Rosenberg; Adam P Spira
Journal:  Semin Neurol       Date:  2017-08-24       Impact factor: 3.420

Review 5.  Psychiatric and behavioral symptoms in Alzheimer's disease and other dementias: etiology and management.

Authors:  Dag Aarsland; Sally Sharp; Clive Ballard
Journal:  Curr Neurol Neurosci Rep       Date:  2005-09       Impact factor: 5.081

Review 6.  Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem.

Authors:  Keith D Hill; Rohan Wee
Journal:  Drugs Aging       Date:  2012-01-01       Impact factor: 3.923

7.  The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.

Authors:  D P Devanand; Jacobo Mintzer; Susan Schultz; David Sultzer; Danilo de la Pena; Sanjay Gupta; Sylvia Colon; Corbett Schimming; Gregory H Pelton; Howard Andrews; Bruce Levin
Journal:  Am J Geriatr Psychiatry       Date:  2012-04       Impact factor: 4.105

8.  Documentation of antipsychotic use and indications for newly diagnosed, nonaggressive dementia patients.

Authors:  Nikhil Dhawan; Avila B Steele; Robert O Morgan; A Lynn Snow; Jessica A Davila; Mark E Kunik
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

9.  Relapse risk after discontinuation of risperidone in Alzheimer's disease.

Authors:  D P Devanand; Jacobo Mintzer; Susan K Schultz; Howard F Andrews; David L Sultzer; Danilo de la Pena; Sanjay Gupta; Sylvia Colon; Corbett Schimming; Gregory H Pelton; Bruce Levin
Journal:  N Engl J Med       Date:  2012-10-18       Impact factor: 91.245

10.  Actigraphy in agitated patients with dementia. Monitoring treatment outcomes.

Authors:  R Mahlberg; S Walther
Journal:  Z Gerontol Geriatr       Date:  2007-06       Impact factor: 1.281

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.